Specialty-specific Evaluation of Virtual care Outcomes: A retrospective QUality and safety analysis (S-EVOQUe).

Publication date: Jan 01, 2025

The objective was to compare specialty-specific 7- and 30-day outcomes between virtual care visits and in-person visits which occurred during the SARS-CoV-2 pandemic. Using administrative data from provincial databases in Ontario, ambulatory care visits occurring virtually and in-person during specific timeframes within the pandemic were analyzed. Virtual care visits were matched with corresponding in-person visits based on multiple baseline patient characteristics. We assessed short-term patient outcomes at 7 and 30 days, including subsequent visits, hospital and ICU admissions, surgeries, and mortality and compared them using multivariate logistic regression. Odds ratios were calculated as measures of association between populations. For statistical significance, we used 99% confidence intervals to account for the increased likelihood of chance findings due to the multiple comparisons conducted. Overall, 9,340,519 visits were compared between populations using a 1:1 match on a 20% random sample of the available eligible visits. Over 70% of patients included were seen by a General Practitioner. With few exceptions and across almost all specialties, revisits, ED visits, admissions, ICU and OR use, and mortality were found to be more frequent for patients seen in person. When using the administrative data available to policy makers, there is no evidence to suggest that, in the short-term, virtual care is less safe than in person care. The causes for worse in-person outcomes are not yet clear although are likely related to the streaming of more acutely unwell patients towards in-person care.

Open Access PDF

Concepts Keywords
Databases Administrative
Hospital Admissions
Match Care
Ontario Icu
Multiple
Outcomes
Pandemic
Patient
Person
Short
Specialty
Specific
Term
Virtual
Visits

Semantics

Type Source Name
disease IDO quality
disease MESH causes
disease MESH Emergency
pathway REACTOME Reproduction
disease MESH death
disease MESH COVID 19 pandemic
pathway REACTOME Translation
drug DRUGBANK 1 2-dichlorobenzene
drug DRUGBANK Ranitidine
disease MESH frailty
drug DRUGBANK Isoxaflutole
drug DRUGBANK Phencyclidine
disease MESH infectious disease
pathway REACTOME Infectious disease
disease IDO entity
disease MESH Privacy
drug DRUGBANK Carboxyamidotriazole
disease MESH appendicitis

Original Article

(Visited 3 times, 1 visits today)